The TOPSY team are delighted to announce that we have received additional funding to do a further follow-up study to understand how women who took part in TOPSY are getting on in the longer term. This follow-up would involve completing one additional questionnaire 4 years since you first started in the TOPSY study. Keep an eye on the website for further information on this additional follow up and for the results so far which will be available later on in the year!
Pelvic organ prolapse (or prolapse) is a common condition in women where the pelvic organs (bladder, bowel or womb) descend into the vagina and cause distressing symptoms that adversely affect quality of life. Two thirds of women initially choose a vaginal support pessary to treat their prolapse symptoms. It is usually fitted at a gynaecological clinic and the woman returns every 6 months to have it removed and changed.
However, it is possible that women could remove, clean and reinsert their pessary themselves at home (self-management), thus offering them more confidence in their ability to maintain and improve their own health.
If you would like to find out information about the TOPSY trial and to see if there are any recruiting sites near you, please contact the TOPSY Glasgow office either by email: TOPSY@gcu.ac.uk or call 0141 331 3516 and ask to speak to the TOPSY Trial mangager , Dr Kirsteen Goodman.
To see if clinic based care or self-management is better at improving women’s quality of life when they are using a vaginal pessary for treatment of pelvic organ prolapse.
What is involved?
For more information about what is involved in the TOPSY study please click on the link for the following;
1. The study flow chart which gives an overview of the study.
2. The five different Patient Information Leaflets for the different aspects of the study.
How long will the study last?
We aim to recruit 330 women to the trial. Recruitment will start in May 2018 and women will be followed up for 18 months. The study will last for 45 months in total and end in July 2021.
This study is funded by the NIHR HTA (project number 16/82/01). More information about NIHR can be found at the NIHR website (www.nihr.ac.uk).
Department of Health disclaimer
The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
The study is sponsored by Glasgow Caledonian University and the Trial office is based at the NMAHP Research Unit at Glasgow Caledonian University
Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate.